Response to "How Important Is the Assessment of Soluble ACE-2 in COVID-19?"

Rieder, Marina; Bode, Christoph; Duerschmied, Daniel; Lother, Achim

Rieder, Marina; Bode, Christoph; Duerschmied, Daniel; Lother, Achim.

Rieder M; Heart Center Freiburg University, Department of Cardiology and Angiology I, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Bode C; Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Duerschmied D; Heart Center Freiburg University, Department of Cardiology and Angiology I, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Lother A; Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Am J Hypertens ; 34(3): 298, 2021 04 02.

Article in English | MEDLINE | ID: covidwho-929800

Subject(s)

COVID-19; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: English Journal: Am J Hypertens Journal subject: Vascular Diseases Year: 2021 Document Type: Article Affiliation country: Ajh

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google